Centenary Institute Lawrence Creative Prize 2016

Play video

Stage: Competition Finished

Matthew Vadas

Professor Mathew Vadas is a physician and internationally renowned immunologist who leads a program of vascular research focused on the mechanisms of inflammation in endothelial cells and on the resultant impact of inflammation on endothelial function in various disease states. His program of drug discovery research uses multidisciplinary biotechnological approaches to uncover novel cellular signaling pathways or molecules involved in endothelial inflammation with the objective of developing new therapeutics. He is the Executive Director of the Centenary Institute, Sydney. Professor Vadas has established major research enterprises in Australia. He was founder and inaugural Director of the Hanson Centre for Cancer Research (now the Hanson Institute). He also was involved in establishing two ASX-listed biotechnology companies and consults to the Australian biotechnology sector. Professor Vadas is one Australia’s most highly cited scientists with >25,500 citations (H index = 85). He is an Inaugural (2001) ISI Award Citation Laureate (one of 33 most cited Australian researchers in all disciplines). His work has made seminal contributions to medical science.

Matthias Hentze

Matthias Werner Hentze, MD is a German scientist. Currently, he is the Director of the European Molecular Biology Laboratory (EMBL) and Professor of Molecular Medicine at Heidelberg University. Matthias Hentze studied medicine in the UK at the medical schools at the University of Southampton, University of Oxford, University of Glasgow and University of Cambridge, and in Germany at the Westfälische Wilhelms-Universität, Münster from which he qualified in 1984. After a short phase of clinical work and supported by a fellowship awarded by the Deutsche Forschungsgemeinschaft (German Research Council), Hentze became a postdoctoral fellow in Dr. Richard Klausner’s laboratory at the National Institutes of Health (NIH), Bethesda, Maryland, United States in 1985. In 1989, he joined the European Molecular Biology Laboratory in Heidelberg as an independent group leader. He served as Dean of the EMBL International Ph.D. Programme from 1996 until 2005, when he became Associate Director of the EMBL and Professor for Molecular Medicine at the University of Heidelberg. Together with Prof. Andreas Kulozik of the Medical Faculty of Heidelberg University, Hentze co-founded the Molecular Medicine Partnership Unit (MMPU) in 2002 and serves as its Co-Director. He is also co-founder of Anadys Pharmaceuticals, San Diego, California. Since 2013, Matthias Hentze is the Director of EMBL, advising and supporting EMBL's Director General, Prof. Iain Mattaj.

Ian Frazer

Professor Ian Frazer was born in 1953 in Glasgow, Scotland, into an academic family. He studied medicine at Edinburgh University and trained as a renal physician and clinical immunologist. He received a BSc(Med) in 1974 and an MB ChB in 1977. In 1974, as part of his studies, Frazer spent three months at the Walter and Eliza Hall Institute of Medical Research in Melbourne. In 1981 Frazer returned to the Walter and Eliza Hall Institute where he continued his clinical training and undertook studies in viral immunology and autoimmunity and became particularly interested in human papilloma viruses (HPV). In 1985 he took up a teaching position with the University of Queensland. When he moved to Brisbane he decided to continue his work with HPV, in particular HPV and cervical cancer. He was awarded a MD from the University of Melbourne in 1988. The work of Frazer with his colleague, the late molecular virologist Dr Jian Zhou, has led to the development of a vaccine which prevents infection with HPV and cervical cancer. Prof Frazer is currently CEO and Director of Research at the Translational Research Institute (TRI).

Jane Visvader

Professor Jane Visvader is a scientist specialising in breast cancer research who works for the Walter and Eliza Hall Institute in Melbourne, Australia. She is the joint head of the Breast Cancer Laboratory with Professor Geoff Lindeman. In 2008, Jane Visvader was a joint recipient of the GlaxoSmithKline Award for Research Excellence for outstanding contribution to Breast Cancer research. Professor Visvader was made a Fellow of the Australian Academy of Science in 2012. Professor Visvader's most recent award is the 2014 Royal Society of Victoria Research Medal for Scientific Excellence in Biomedical & Health Sciences.

Michael Parker

Professor Michael Parker is Deputy Director of St. Vincent’s Institute of Medical Research in Melbourne where he is heads its Structural Biology Laboratory and the ACRF Rational Drug Discovery Centre. He is an NHMRC Senior Principal Research Fellow and a Professorial Fellow at the Bio21 Institute, Melbourne University. He has published almost 300 papers and his work has been recognised with numerous awards including the 1999 Gottschalk Medal of the Australian Academy of Science, a 2006 Federation Fellowship from the Australian Research Council, the 2011 Lemberg Medal of the Australian Society for Biochemistry and Molecular Biology, the 2011 Ramaciotti Medal for Excellence in Biomedical Research and the 2012 Federation of Asian and Oceanian Biochemists and Molecular Biologists Award for Research Excellence. He was elected a Fellow of the Australian Academy of Science in 2010.

Marc Feldmann

Professor Sir Marc Feldmann is a pre-eminent immunologist at the University of Oxford where he is Head of the Kennedy Institute of Rheumatology and leads the Cytokine and Cellular Biology section. Prof Sir Feldmann has authored over 600 published papers reflecting an overarching commitment to both the cellular aspects of inflammatory autoimmune biology messenger molecules, cytokines and therapeutic applications.

 Funding Available

$36,000

Host

Many of our senior researchers are specialist clinicians at Royal Prince Alfred Hospital and lecturers at the University of Sydney. Their direct, personal experience with patients inspires their work to improve and save lives. Our close ties with the University and Hospital mean our scientists are not isolated from the people who are affected by the major diseases we are working to overcome. ...